Complexity of molecular forms of B-type natriuretic peptide in heart failure

Heart

Volumn 99, Issue 10, 2013, Pages 677-679

  Nishikimi, Toshio ^a   Kuwahara, Koichiro ^a   Nakagawa, Yasuaki ^a   Kangawa, Kenji ^b   Minamino, Naoto ^b   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; MESSENGER RNA;

CONGESTIVE HEART FAILURE; CROSS REACTION; DISEASE SEVERITY; HEART FAILURE; HEART MUSCLE CELL; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; MASS SPECTROMETRY; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN GLYCOSYLATION; REVIEW;

BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS;

EID: 84876666455     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302929     Document Type: Review

References (15)

1. Sudoh T, Kangawa K, Minamino N, et al. A new natriuretic peptide in porcine brain. Nature 1988;332:78-81. (Pubitemid 18083551)
2. Nishikimi T, Kuwahara K, Nakao K. Current biochemistry, molecular biology, and clinical relevance of natriuretic peptides. J Cardiol 2011;57:131-40.
3. Vanderheyden M, Bartunek J, Goethals M, et al. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin Chem Lab Med 2009;47:248-52.
4. Lam CS, Burnett JC Jr, Costello-Boerrigter L, et al. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 2007;49:1193-202. (Pubitemid 46400332)
5. Heublein DM, Huntley BK, Boerrigter G, et al. Immunoreactivity and guanosine 3, 5-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007;49:1114-49.
6. Hawkridge AM, Heublein DM, Bergen HR III, et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 2005;102:17442-7. (Pubitemid 41740885)
7. Niederkofler EE, Kiernan UA, O'Rear J, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008;1:258-64.
8. Miller WL, Phelps MA, Wood CM, et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail 2011;4:355-60.
9. Waldo SW, Beede J, Isakson S, et al. Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol 2008;51: 1874-82. (Pubitemid 351615249)
10. Nishikimi T, Minamino N, Ikeda M, et al. Diversity of molecular forms of plasma brain natriuretic peptide in heart failure-different proBNP-108 to BNP-32 ratios in atrial and ventricular overload. Heart 2010;96:432-9.
11. Nishikimi T, Ikeda M, Takeda Y, et al. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart 2012;98:152-61.
12. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-8. (Pubitemid 46349497)
13. Hammerer-Lercher A, Halfinger B, Sarg B, et al. Analysis of circulating forms of proBNP and NT-proBNP in patients with severe heart failure. Clin Chem 2008;54:858-65. (Pubitemid 351671596)
14. Schellenberger U, O'Rear J, Guzzetta A, et al. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 2006;451:160-6.
15. Semenov AG, Postnikov AB, Tamm NN, et al. Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem 2009;55: 489-98.